PaxMedica Prepares NDA Submission for Suramin and Pivotal FDA Meeting for PAX-101
PaxMedica prepares NDA submission to FDA for suramin and pivotal meeting for PAX-101, demonstrating commitment to advancing healthcare solutions and addressing crucial public health needs.
This news matters because it highlights the efforts of PaxMedica in advancing healthcare solutions for neurological disorders. The outcomes of the FDA meeting and the potential approval of the NDA could have a significant impact on the treatment of Human African Trypanosomiasis and autism, addressing crucial public health needs.
